cagrilintide novo A new drug combo of semaglutide (GLP-1 receptor agonist) with (amylin analogue) failed to do as well as tirzepatide (GLP-1/GIP receptor agonist). The future of these medicines is hitting different receptors Novo Nordisk files for FDA

From a billing perspective, CPT 62321 has strict coding and documentation requirements

The comprehensive panel at weeks eight to twelve provides stable values for long-term protocol planning

Document MELD (Model for Endstage Liver Disease) score and indications for transplant evaluations when billing highlevel E/M visits

Maximum: One injection per 24 hours

Its multifaceted approach, including appetite suppression and slowed gastric emptying, has been shown to result in significant reductions in body fat

The following resources are also available to read on WADAs website: The full 2026 Prohibited List The WADA 2026 Summary of Major Modifications and Explanatory Notes The 2026 Monitoring Program which includes substances not currently on the List but are being monitored by WADA for potential patterns of misuse in sport